5-Fluorouracil, High-Dose Folinic Acid and Mitomycin C Combination Chemotherapy in Previously Treated Patients with Advanced Colorectal Carcinoma

References

• Launoy G, Grosclaude P, Pienkowski P, et al. Les can-cers digestifs en France. Comparaison de l'incidence dans 7 departements et estimation de l'incidence pur la France entiere. Gastroenterol Clin Biol 1992; 16: 633–638.
   Google Scholar
• Moertel CG, Fleming TR, MacDonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352–358.
   PubMed Web of Science ®Google Scholar
• IMPACT Investigators: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 106: 939-944.
   Google Scholar
• Scheithauer W, Rosen H, Kornek CV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993; 306: 752–755.
   PubMed Web of Science ®Google Scholar
• Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992; 10: 904–911.
   Google Scholar
• Machover D, Schwarzenberg L, Goldschmidt E, et al. Treatment of colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study. Cancer Treat Rep 1982; 66: 1803-1807.
   Google Scholar
• Poon MA, O'Connell MJ, Moertel CG. Biochemical modulation of fluorouracil: evidence of significant improve-ment of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407–1418.
   PubMed Web of Science ®Google Scholar
• Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896–903.
   Google Scholar
• Lokich J, Fine N, Bothe A. Protracted ambulatory venous infusion of 5FU. Am J Clin Oncol 1983; 6: 103–107.
   PubMed Web of Science ®Google Scholar
• Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluo-rouracil-based chemotherapy. J Clin Oncol 1997; 15: 251–260.
   PubMed Web of Science ®Google Scholar
• Machover D, Diaz-Rubio E, De Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treat-ment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7: 95–98.
   PubMed Web of Science ®Google Scholar
• Aschele C, Sobrero A, Faderan MA, Bertino JR. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992; 52: 1855-1864.
   Google Scholar
• Sobrero A, Aschele C, Guglielmi AP, Mori AM, Melioli CC, Rosso R. Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J Natl Cancer Inst 1993; 85: 1937–1944.
   PubMedGoogle Scholar
• Degramont A, Krulik M, Cady J. High dose folinic acid and 5 fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 1988; 24: 1499-1503.
   Google Scholar
• De Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup Study. J Clin Oncol 1997; 15: 808–815.
   PubMed Web of Science ®Google Scholar
• Crooke ST, Bradner WT. Mitomycin C: a review. Cancer Treat Rev 1979; 3: 121–139.
   Google Scholar
• Sartorelli AC, Booth BA. The synergistic anti-neoplastic activity of combination of mitomycin with either 6-thioguanine or 5-fluorouracil. Cancer Res 1965; 25: 1993-2000.
   Google Scholar
• Russello O, Romaniniy A, Civalleri D, Rosso R, Nicolin A, Sobrero A. Time-dependant interactions between 5-fluo-rouracil and mitomycin C on a human colon carcinoma cell line, HCT-8, in vitro. Eur J Cancer Clin Oncol 1989; 25: 571-572.
   Google Scholar
• Becouarn Y, Brunet R, Bussieres E, Maree D. 5-Fluorouracil, high-dose folinic acid, and mitomycin C combina-tion chemotherapy in advanced gastrointestinal adenocarcino-mas. A pilot study. Oncology 1988; 45: 269–272.
   PubMed Web of Science ®Google Scholar
• Kim S, Kim C, Kim R. A phase II trial of 5-fluorouracil, leucovorin and mitomycin in gastrointestinal cancer. Proc Am Soc Clin Oncol 1991; 10: 140.
   Google Scholar
• Seitz JF, Diaw A, Giovannini M, Perrier H, Gouvernet J. Association 5-fluorouracile, acide folinique a haute dose et mitomycine C dans le traitement des cancers digestifs avancês. Bull Cancer (Paris) 1994; 81: 134–137.
   PubMedGoogle Scholar
• Ducreux M, Rougier P, Voni R, Gautrin S, Kac J, Armand JP, Bonnay M. Lack of relationship between plasma concentration and clinical parameters in patients with metasta-tic colorectal cancer treated with prolonged infusion of 5-fluo-rouracil and oral leucovorin. Proc Am Assoc Cancer Res 1996; 37: 408a.
   Google Scholar
• Izzo J, Fandi A, Villalobos W, et al. Low dose protract-ed continuous 5-fluorouracil (FU) infusion in solid tumors. J Infusion Chemother 1994; 4: 135–139.
   Google Scholar
• Palmieri G, Gridelli C, Airoma G, et al. Second-line chemotherapy of advanced colorectal cancer with sequential high-dose methotrexate and 5-fluorouracil. J Chemother 1991; 3: 55–60.
   PubMed Web of Science ®Google Scholar
• Perez J, Lacava J, Sabatini C, et al. Interferon and 5-fluorouracil as second-line therapy in advanced colorectal can-cer. Proc Am Soc Clin Oncol 1996; 15: 222a.
   Google Scholar
• Cascinu S, Fedeli A, Luzi Fedeli S, Catalano G. Salvage chemotherapy in colorectal cancer patients with good perfor-mance status and young age after failure of 5-fluorouracil/leu-covorin combination. J Chemother 1992; 4: 46–49.
   PubMed Web of Science ®Google Scholar
• Adenis A, Carlier D, Darloy F, Pion JM, Bonneterre J, Demaille A. Cytarabine and cisplatin as salvage therapy in patients with metastatic colorectal cancer who failed to 5-fluo-rouracil + folinic acid regimen. Am J Clin Oncol 1995; 18: 158–160.
   PubMed Web of Science ®Google Scholar
• Ardalan B, Chua L, Tian EM. A phase II study of week-ly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991; 9: 625–630.
   PubMed Web of Science ®Google Scholar
• Weh HJ, Wilke HJ, Dierlamm J. Weekly therapy with folinic acid and high-dose 5-fluorouracil 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 1994; 5: 233–237.
   PubMed Web of Science ®Google Scholar
• Jager E, Klein 0, Wachter B, Muller B, Braun U, Knuth A. Second-line treatment with high dose 5-fluorouracil and folinic acid in advanced colorectal cancer refractory to standard dose 5-fluorouracil treatment. Oncology 1995; 52: 470–473.
   Google Scholar
• Louvet C, Bleiberg H, Gamelin E, et al. Oxaliplatin (L-OHP) synergistic clinical activity with 5-fluorouracil in FU resis-tant colorectal cancer patients is dependent on FU ± folinic acid schedule. Proc Am Soc Clin Oncol 1996; 15: 206a.
   Google Scholar
• Seitz JF, Ychou M, Bexon A, et al. Etude de phase VII avec escalade de dose du CPT11 associê au 5FU + acide folinique (schema LV5FU2) toutes les 2 semaines dans le traitement du cancer colorectal rêfractaire au 5FU. Bull Cancer 1997; 84: 564 (abstr.)
   Google Scholar
• Kikkawa N, Taguchi T, Sakai L, et al. Combination therapy of high dose doxifluridine (5'-DFUR) + mitomycin C (MMC) for advanced or recurrent colorectal cancer. Joint Research Group in the Osaka Area for Combination Therapy of 5'-FDUR with Other Drugs. Jpn J Cancer Chemother 1993; 20 (1): 117-123.
   Google Scholar
• Isacoff W, Eilber F, Jacobs Ad, Taylor o. A phase II trial of continuous infusion 5-fluorouracil, calcium leucovorin, mitomycin C, and dipyridamole in patients with advanced colon cancer [abstract]. Proc Am Soc Clin Oncol 1994; 13: 216.
   Google Scholar
• Conti JA, Kemeny NE, Saltz LB, McKenzie AA, Grossano DD, Bertino JR. Continuous infusion fluorouracil/leucovorin and bolus mitomycin C as a salvage regimen for patients with advanced colorectal cancer. Cancer 1995; 75: 769–774.
   PubMed Web of Science ®Google Scholar
• Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, Massey A. A prospective randomised trial of pro-tracted venous infusion (PVI) 5FU with or without mitomycin C (MMC) in advanced colorectal cancer. Proc Am Soc Clin Oncol 1997; 16: 271a.
   Google Scholar
• Stathopoulos GP, Stergiou GS, Golematis B, Thalassinos N, Fillipakis M. Effect of adriamycin, 5 fluorouracil and mitomycin C combination chemotherapy in advanced col-orectal cancer. Oncology 1995; 52 (4): 306–309.
   PubMed Web of Science ®Google Scholar
• Buroker TR, Kim PN, Baker LH, Ratanatharathorn V, Wojtaszok B, Vaitkevicius VK. Mitomycin C alone and in com-bination with infused 5-fluorouracil in the treatment of dissem-inated gastrointestinal carcinoma. Med Pediatr Oncol 1978; 4: 35–42.
   PubMedGoogle Scholar
• Nordlinger B, Jaeck D, Guiguet M. Surgical resection of hepatic metastases. Multicentric retrospective study by the French Association of Surgery. In Nordlinger B, Jaeck D (eds): Treatment of Hepatic Metastases of Colorectal Cancer. Springer-Verlag, Paris, France, 1992: 129-146.
   Google Scholar
• Andre T, Bensmaine MA, Louvet C, et al. Addition of oxaliplatin (Eloxatine) to the same leucovorin and 5-fluo-rouracil bimonthly regimens after progression in patients with metastatic colorectal cancer: preliminary report. Proc Am Soc Clin Oncol 1997; 16: 270a.
   Google Scholar